Clinical Trial Update: Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update notes safety and efficacy evaluation of daratumumab in patients with anti-AQP4 antibody positive neuromyelitis optica spectrum disorders (…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica
• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• Daratumumab (Darzalex) (daratumumab)

Snippet

Sponsor: Tianjin Medical University General Hospital | Conditions: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING